Lavipharm Sa · ATHEX:LAVI

Lavipharm Sa — Investor Presentation (2014)

25 slides from Lavipharm Sa's investor presentation, 2014

  1. Slide 1: Corporate Presentation

    Corporate Presentation 060 CG Lavipharm

  2. Slide 2: Who we are

    Who we are  A fully integrated pharmaceutical group in Greece with a 100-year history  We develop, manufacture, import, market, distribute and export pharmaceutical, OTC and dermocosmetic products  Partner of choice for major international pharmaceutical and consumer health companies in Greece an

  3. Slide 3: Historical Highlights

    Historical Highlights 1911 Establishment of Lavipharm 1914 Launch of Digitaline, an innovative cardiovascular product, in Greece 1958 Launch of Nitroglycerin Controlled Release tablets 1976 Dr. A. Lavidas with new management team 1977 Collaboration with L’Oreal - first to sell cosmetics through phar

  4. Slide 4: Historical Highlights

    Historical Highlights 1996 Acquisition of U.S. based R&D unit specialised in TDDS (now Lavipharm Laboratories Inc) 1997 Launch of patented acne epidermal patch worldwide by L’Oreal 2000 Acquisition of 30% of Phasex (U.S.A.) specialized in SCF 2006 FDA approval of Lavipharm's fentanyl transdermal sys

  5. Slide 5: Operation Centers

    Operation Centers Greece France Italy  Headquarters  Rx  Rx  Production / Distribution  Dermocosmetics  Commercial activity  Food Supplements Pharma (Rx & OTC), Dermocosmetics U.S.A.  NJ: Commercial Activity Pharma US & Canada  R&D Pharma/ OTC

  6. Slide 6: Lavipharm S.A.

    Lavipharm S.A. Headquarters: Peania, Attica Turnover 2013 : € ~30 million Listed on the Athens Exchange since 1995 (ASE : ΛΑΒΙ)

  7. Slide 7: Core Activities

    Core Activities I. Research & Development II. Manufacturing III. Pharmaceuticals IV. Consumer Health / OTC V. Dermocosmetics VI. Wholesaling - Logistics VII. Pharmacy Services

  8. Slide 8: I. Research & Development

    I. Research & Development Greece Headquarters, Lavipharm SA  Natural Products  Commercial / Industrial Production USA New Jersey- Lavipharm Laboratories  Drug Delivery Technologies  Clinical Manufacturing

  9. Slide 9: I. Research & Development: Pharma

    I. Research & Development Drug Pre-Formulation Dosage Formulation Discovery Development Development Pharma Lavipharm Field of Activity Formulation/ Drug Delivery Molecule Particle Design Devices Design • Organic • Physical • Pharmaceutics Chemistry Chemistry • Physical Chemistry • Biotechnology • Ph

  10. Slide 10: I. Research & Development: Pharma

    I. Research & Development  Transdermal (TDDS) Pharma  Intra – oral (IODS)  Osmotic (OODS) Protective Backing Removable layer Drug in adhesive matrix

  11. Slide 11: Cosmetic Technologies

    I. Research & Development Cosmetic Technologies

  12. Slide 12: II. Manufacturing

    II. Manufacturing PHARMACEUTICALS Tablets 830 million tabs Capsules 47 million caps TTDS 140 million pouches Liquid 23 million bottles Creams & Ointment 8 million tubes COSMETICS / OTC Creams & Emulsions 4.5 million tubes Shampoos & Lotions 6 million bottles

  13. Slide 13: III. Pharmaceuticals

    III. Pharmaceuticals  Therapeutic Categories: a) Cardiology b) Chronic Pain & Oncology c) CNS d) Dermatology e) General Medicine & Respiratory f) Urology

  14. Slide 14: III. Pharmaceuticals: Lavipharm's Pharmaceutical Products

    III. Pharmaceuticals Lavipharm’ s Pharmaceutical Products  Chronic Pain &  Cardiology:  General Medicine, CNS & Respiratory: Oncology:  Nitrong TTS®  Caprilon®  Mundisal Gel®  Fentadur®  Nitrong® 2,6mg  Memodrin®  Terbigram®  Prostaplant ®  Nitrolingual  Pricital®  Lanex ®  Kerlone® 

  15. Slide 15: III. Pharmaceuticals: Greece Main cooperations

    III. Pharmaceuticals Greece Main cooperations

  16. Slide 16: III. Pharmaceuticals: Global Market

    III. Pharmaceuticals Global Market  NITROGLYCERIN TRANSDERMAL (launched in EU/Canada)  FENTANYL TRANSDERMAL (launched in most countries of the EU)  OTHER TRANSDERMALS (under development)  THIN FILM OTC products (under development)

  17. Slide 17: III. Pharmaceuticals: Global Market Main Distributors

    III. Pharmaceuticals Global Market Main Distributors

  18. Slide 18: International presence

    International presence * be >’ lel 640 CG Lavipharm

  19. Slide 19: IV. Consumer Health / OTC

    IV. Consumer Health / OTC Main Products:  BETADINE (antiseptic)  LAVISEPT (instant antiseptic)  ALGON (pain reliever)  IVALITEN, LAVITEN (anti-lice)  LACTAL (gyn)  TILMAN (supplements/cough & cold remedies)

  20. Slide 20: IV. Consumer Health/OTC: Main Cooperations

    IV. Consumer Health/OTC Greece Main Cooperations

  21. Slide 21: V. Dermocosmetics

    V. Dermocosmetics  Brand philosophy “20 year expertise in skin biology”  Promoted to Dermatologists  Clinically proven efficacy  Sold exclusively in pharmacies in 16 countries globally MORE THAN 20 YEARS OF KNOWLEDGE IN THE BIOLOGY OF THE SKIN

  22. Slide 22: VI. Wholesaling – Logistics

    VI. Wholesaling – Logistics  Logistics services to pharmacies, hospitals and wholesalers  Fully automated warehouse (600 orders per hour)

  23. Slide 23: VII. Pharmacy Services

    VII. Pharmacy Services We provide our customers (pharmacies) with:  Fully integrated supply chain center  Integrated I.T. system  Agreements with health care products' suppliers  Up-to-date product data base with continuous back up  Educational / Training programs  Marketing activities  Pione

  24. Slide 24: Slide 24

  25. Slide 25: Visit us @ www.lavipharm.com

    Visit us @ www.lavipharm.com

Lavipharm — Investor Presentation (2014) on 6ix